⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
HIF-1α/BNIP3 Pharmacological MSC Rejuvenation
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — Syringaresinol Attenuates Aging-Associated Ferroptosis-Relevant Stress Through an HIF-1α-GPX4 Defense Axis.: cross-connection with syringaresinol: Both invoke HIF-1α as a protective axis in aging contexts — syringaresinol as a small-molecule inducer of HIF-1α–GPX4 anti-ferroptotic defense, versus pharmacological HIF-1α/BNIP3 engagement for MSC rejuvenation. (novelty: 3)
- 2026-08-26 — Rapamycin attenuates age-related atrial remodeling and fibrillation by targeting HIF-1α-mediated metabolic dysregulation.: cross-connection with rapamycin-mtor: Both findings implicate HIF-1α as a druggable node in aging phenotypes; rapamycin here suppresses HIF-1α-driven atrial metabolic remodeling, while the MSC rejuvenation work exploits HIF-1α/BNIP3 pharmacologically — opposite-sign manipulations of the same axis in different tissues. (novelty: 3)
- 2026-07-09 — Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.: 2025 review highlights the WAC–PINK1–Parkin axis in MSC aging and integrates HIF-1α/BNIP3-driven mitophagy as a cell-type-specific mitochondrial ubiquitination lever for rejuvenating aged mesenchymal stem cells (mechanistic review, no clinical outcomes). [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.
09-jul-2026
novelty 3
per-area 3
strengthens